Skip to content

A study for percutaneous microwave ablation in the treatment of peripheral ground-glass opacity lung adenocarcinoma

A study for percutaneous microwave ablation in the treatment of peripheral ground-glass opacity lung adenocarcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018099
Enrollment
Unknown
Registered
2018-08-30
Start date
2018-10-30
Completion date
Unknown
Last updated
2018-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral ground-glass opacity lung adenocarcinoma

Interventions

Group 1:MWA

Sponsors

Shanghai Chest Hospital, Shanghai Jiao Tong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) patient aged older than 18 years; 2) peripheral GGO lesions are found in patients' chest CT ,and are pathologically confirmed as non-small cell lung cancer, and preoperative evaluation is completed (chest enhanced CT pet-ct and/or other examinations); 3) thin-layer CT(5mm thick) of the patient suggeste peripheral GGO lesions (8mm< lesion diameter 5cm), with 25% of the glassy components in the lesions; 4) after multi-disciplinary evaluation, the patient is not suitable for surgical treatment, and agree to initially receive CT-guided transthoracic MWA or SBRT treatment; 5) patients have good compliance with the examination and follow-up, understand the situation of this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) the general condition of the patient is extremely poor, unable to tolerate partial treatment through chest wall or have contraindications; 2) the patient has received other treatment for GGO lesions before, or have regional lymph node metastasis or distant metastasis; 3) poor compliance; 4)participants who have other situations which are considered inappropriate for in this study.

Design outcomes

Primary

MeasureTime frame
Progression-free survival time (PFS);

Secondary

MeasureTime frame
Objective Response Rate, ORR;Overall Survival,OS;

Countries

China

Contacts

Public ContactJiayuan Sun

Shanghai Chest Hospital, Shanghai Jiao Tong University

xkyyjysun@163.com+86 18017321598

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026